Directa Plus and Iterchimica commence UK road surface trial
Francesca Morgan
Company News - 2 mins
10:55, 8th November 2019

Directa Plus (DCTA) FOLLOW announced on Friday alongside its partner, Iterchimica, a world leader in products that enhance asphalt performance, the commencement of their UK road trial for graphene enhanced road surfaces.

According to Founder and CEO of Directa, Giulio Cesareo, the trial is considered crucial “in proving the business and use case for the next generation of graphene enhanced road surfaces.”

The trial, to take place in Curbridge, Oxfordshire, will involve laying asphalt concrete with a proprietary graphene-enhanced modifier to refurb two upper layers of a 750m long section of road.

By comparing asphalt concrete with the super modifier to a traditional asphalt surfacing, the trial will assess service life, resistance to the passage of vehicles, resistance to deformation and permanent plastic deformation.

Oxfordshire County Council has permitted the commencement of the trial, and the group’s prime contractor will be Skanska AB, a multinational construction company.

The graphene-enhanced modifier is the result of a three-year research with a patent filed in 2017 and has the potential to vastly improve the quality of road surfaces.

"This technology will allow governments to supply better quality roads for drivers and other road users, at better value for money, and in a more environmentally sustainable way,” commented Mr Cesareo.

Significantly, asphalt concrete with super modifier, once laid, can be 100% recycled, reducing the extraction of new materials from quarries and first-use bitumen.

"Working with leading companies such as Iterchemica to bring the benefits of G+ graphene enhanced products and materials to market is a key part of Directa Plus' strategy across all our key industrial verticals,” Mr Cesareo added.

Follow News & Updates from Directa Plus here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist